| Disease | REACTIONS CONSIDERED POSSIBLY RELATED TO TREATMENT WERE MILD GASTROINTESTINAL EVENTS, PREDOMINANTLY BURPING. PETASITES EXTRACT 75 MG BID IS MORE EFFECTIVE THAN PLACEBO AND IS WELL TOLERATED AS A PREVENTIVE THERAPY FOR MIGRAINE.
EBO GROUP. THE PROPOTION OF PATIENTS WITH A >OR=50% REDUCTION IN ATTACK FREQUENCY AFTER 4 MONTHS WAS 68% FOR THE PATIENTS IN THE PETASITES EXTRACT 75 MG ARM AND 49% FOR THE PLACEBO ARM (P<0.05). RESULTS WERE ALSO FREQUENTLY REPORTED ADVERSE
MENT PERIOD. OVER 4 MONTHS OF TREATMENT, IN THE PER-PROTOCOL ANALYSIS, MIGRAINE ATTACK FREQUENTLY REDUCED BY 48% FOR PETASITES EXTRACT 75 MG BID(P=0.0012 VS PLACEBO), 36% FOR PETASITES EXTRACT 50MG BID (P=0.127 VS PLACEBO), AND 26% FOR THE PLACE
WERE AGES 18 T0 65, AND HAD AT LEAST TWO TO SIX ATTACKS PER MONTH OVER THE PROCEDING 3 MONTHS. THE MAIN OUTCOME MEASURE WAS THE DECREASE IN MIGRAINE ATTACK FREQUENCY PER MONTH CALCULATED AS PERCENTAGE CHANGE FROM BASELINE OVER A 4 MONTH TREAT
THIS IS A THREE-ARM, PARALLEL-GROUP, RANDOMIZED TRIAL COMPARING PETASITES EXTRACT 75 MG BID, PETASITES EXTRACT 50 MG BID, OR PLACEBO BID IN 245 PATIENTS WITH MIGRAINE. ELIGIBLE PATIENTS MET INTERNATIONAL HEADACHE SOCIETY CRITIRIA FOR MIGRAINE, |